Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasms 1Leukemia, Myeloid 1

Interventions

Specimen Handling 454Magnetic Resonance Spectroscopy 347pembrolizumab 289Biopsy 244Carboplatin 230Cisplatin 194Cyclophosphamide 186Paclitaxel 164Nivolumab 154Gemcitabine 151Radiotherapy 125Bevacizumab 124Dexamethasone 113fludarabine 100Pemetrexed 99Fluorouracil 94Doxorubicin 92durvalumab 91Radiation 91Docetaxel 91venetoclax 89Rituximab 88Oxaliplatin 88atezolizumab 87Leucovorin 79Capecitabine 76Prednisone 75Lenalidomide 70Etoposide 69X-Rays 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide × 30 days × Clear all
NCT06235801 2026-06-02

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT06150157 2026-05-12

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Janssen Research & Development, LLC

Phase 1 Recruiting
220 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡